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Abstract: In numerous recent papers plasma chemistry of non equilibrium plasma sources operating at atmospheric
pressure has been linked to plasma medical effects including sterilization. In this paper we present a study
of the effectiveness of an atmospheric pressure plasma source, known as plasma needle, in inhibition of
the growth of biofilm produced by methicillin resistant Staphylococcus aureus (MRSA). Even at the lowest
powers the biofilms formed by inoculi of MRSA of 104 and 105 CFU have been strongly affected by plasma
and growth in biofilms was inhibited. The eradication of the already formed biofilm was not achieved and it
is required to go to more effective sources.
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1. Introduction
The majority of bacteria in nature have a tendency to in-teract and grow in close association with surfaces, form-
∗E-mail: maja.miletic@stomf.bg.ac.rs (Corresponding author)†E-mail: nevena@ipb.ac.rs
ing biofilms. A biofilm can be defined as a surface-attached community of bacteria growing embedded in aself-produced matrix composed of extracellular polymericsubstances (EPS) [1, 2]. Bacteria within biofilms havemetabolic and physiological capabilities which are notassociated with individual, unattached cells. Notableamongst these unique properties is high level of resis-tance to antibiotics and chemical/physical decontamina-tion procedures. Therefore, bacteria living in biofilms are
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difficult or even impossible to eradicate [1, 2]. The aimof this investigation was to evaluate the antimicrobialactivity of a non-thermal atmospheric plasma, generatedby a specifically designed plasma needle device, againstbiofilms produced by methicillin resistant Staphylococ-cus aureus (MRSA). Recently atmospheric pressure dis-charges have been developed as sources of low tempera-ture plasmas at atmospheric pressure and, thus, it becamepossible to develop plasma medical applications [3, 4].Most studies have shown very good results [5–8] in di-rect contact of plasmas with microorganisms. Howeversterilization of planktonic samples and biofilms proved tobe more difficult [9–13]. In this paper we extend the ap-plication of a plasma needle that has been tested in di-rect contact with plant and mammalian cells [14, 15] andfor planktonic samples of bacteria [15] to study steriliza-tion of biofilms. It is estimated that up to 80% of hu-man bacterial infections are actually biofilm-associated.Biofilm formation has typically been implicated in per-sistent tissue infections and medical device-related infec-tions [16], although the role of biofilm has recently beenrecognized in acute infections as well [17]. Species of thegenus Staphylococcus, in particular S. aureus and S. epi-dermidis, are among the most frequent causative agentsof biofilm-mediated infections [18, 19]. The most impor-tant S. aureus diseases that have a demonstrated biofilmcomponent are osteomyelitis, medical device-related in-fections, wound infections and endocarditis. Worldwidedissemination of MRSA strains that display resistance toall beta-lactam antibiotics, further complicates preventionand treatment of these diseases [18, 19]. Since antibiotictreatment often fails to overcome biofilm-associated in-fections, particularly those caused by multidrug resistantbacteria, it is apparent that development of alternativestrategies for preventing and/or treating these infectionsis of great importance. Further research is needed to un-derstand molecular mechanisms of biofilm formation bybacteria. For example, it has recently been shown thatS. aureus cysteine proteases ScpA and SspB, so calledStaphopains, are the key modulators of biofilm productionby this bacterium and that development of strategies toup-regulate the Staphopains could be a novel approachto treating S. aureus biofilm infections [20]. Lately, it wasshown that low-temperature gas plasma presents a power-ful medical tool in general [3, 4, 21]. Cold plasma can suc-cessfully eradicate microorganisms [22–24] and this factis exploited in plasma sterilization of medical equipmentand instruments [25, 26]. Compared to common methodsused in health-care facilities like steam under pressure,dry heat, ethylene oxide gas and liquid chemicals, plasmaoffers non-toxicity and treatment of heat sensitive instru-ments without rapid degradation. Plasmas can offer dif-
ferent principles of inactivation mechanisms like etchingor sputtering of membranes of bacteria or endospore coat,charging of the bacterial cell membrane, DNA modifica-tions based on strand breaks [27]. For all inactivationmechanisms maximum result is obtained through syner-gistic effects of all plasma agents (electrons, ions, pho-tons, electric fields, radicals and metastables) [28] thattarget many cellular components and metabolic processesin bacteria. This explains one of the major advantages ofcold atmospheric plasmas i.e. multiple targets in bacterialcells make the emergence of resistance mechanisms lesslikely [9]. In addition, plasma chemistry is important asgeneration of radicals or active molecules at the surfacein very small quantities may trigger a biological responsewith only a small amount of reactive species that wouldotherwise be very toxic. The effectiveness of the steriliza-tion process depends not only on plasma composition, butalso on intrinsic properties of the sample. For example,individual bacteria are easily inactivated by UV radiationat a timescale of seconds [29]. On the other hand, only UVradiation is not sufficient when bacteria are contained insome surrounding medium, especially if this medium hasa supporting structure. Good examples are bacteria insuspensions and bioflims [30]. Our previous work showedplasma sterilization of bacteria in planktonic sample de-spite the obvious “shielding” by the liquid medium [15].Independent of our work, Joshi et al. reached similar con-clusions [13]. A large number of papers followed [31–33].In this sense, biofilms represent an even more challeng-ing task because bacteria are shielded by the polymericmatrix. Plasma cannot easily penetrate complex porousand hollow structures and, in addition, a synergetic ef-fect of agents is needed for biomaterial removal and in-depth effects on multilayer stacks. As we move towardsthe in-vivo applications, the situation gets more compli-cated due to the presence of biofilms containing severalspecies of bacteria, blood, fat, and other body products likesweat or saliva. Despite the problems, application of low-temperature plasmas at atmospheric pressure presents apromising antibiofilm approach according to the literature.
2. Experimental
2.1. Bacterial strain and growth conditions
The MRSA isolate used in this study was recovered froma surgical wound and identified as MRSA by BD PhoenixAutomated Microbiology System (Becton Dickinson Diag-nostic Systems, Sparks, MD). Identification to the specieslevel was confirmed by detection of the nuc gene [34]whilst resistance to meticillin was established by poly-merase chain reaction (PCR) for the mecA gene [35]. Pre-
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vious evaluation identified the strain as a strong biofilmproducer [36]. The MRSA strain was transferred froma frozen stock culture onto tryptic soy agar and incu-bated aerobically for 24 hours at 35 − 37◦C. The bacte-rial suspensions were prepared as follows: a few colonieswere suspended in physiological saline and the turbidityof the suspension was adjusted to 0.5 McFarland stan-dard (≈ 108 CFU mL−1) by using a Densimat photometer(BioMerieux, France). The final testing inocula used inthis study ranged from 106 to 104 CFU per well of a ster-ile 96 well-flat bottom polystyrene microtiter plate.
2.2. Plasma source
In this study we used a plasma needle device (developed inour laboratory at the Institute of Physics of the Universityof Belgrade) that was designed for biomedical applicationsand tested with numerous diagnostic procedures [14, 37].The device is similar in concept to the one developed byStoffels et al. [38, 39]. The plasma needle consists of acentral wolfram electrode (0.5 mm in diameter) covered bya ceramic tube. The ceramic tube serves to insulate thecentral electrode from the working gas [14]. The poweredelectrode and the ceramic tube are placed in a glass tubewith a 4 mm inner and 6 mm outer diameter. Heliumis flowing between the ceramic and the glass tube andallows plasma formation only at the tip of the electrode.The body of the plasma needle is made of Teflon. Plasmaneedle operates at 13.56 MHz with the electrical circuitconsisting of a signal generator, amplifier and matchingnetwork.Electrical characterization of the system is performed byusing derivative probes. The probes are placed as closeas possible to the tip of the needle in order to obtainthe actual power transmitted to the plasma. An oscillo-scope and a computer are used to capture and processthe signals. The collected signals are transferred to thefrequency domain by using Fast Fourier transform. In thisdomain current and voltage signals are corrected accord-ing to calibration curves. Conversion back to the timedomain by inverse fast Fourier transform is carried outin the final stage. The difference between signals whenplasma is lit and without the plasma (no helium flow) con-tains the information about the power transferred to theplasma. Knowledge of power transmitted to the plasmagives us a good control of treatment conditions.
2.3. Biofilm growth
Microtiter biofilm assay was carried out in accordancewith the protocol described by Stepanović et al. [40]. Eachwell contained 180 µL of brain heart infusion broth (BHI)
supplemented with 1% glucose and 20 µL of bacterial sus-pension. The negative control wells contained 200 µL BHIsupplemented with 1% glucose, only. In order to assessthe inhibitory effects of non-thermal plasma on growth ofMRSA biofilm, the bacteria were exposed to the plasma5 h after the addition of bacterial suspension to medium.After plasma treatment the biofilms were allowed to growfor 24 h at 35 − 37◦C and then quantified. To evalu-ate possible effects of non-thermal plasma on the formedMRSA biofilm, the inoculated plates were first incubatedfor 24 h at 35− 37◦C and then exposed to plasma treat-ment. Quantification of the biofilm was performed afterthe plasma treatment.
2.4. Plasma treatment conditions
The same set of conditions was applied both to freshlyinoculated plates and plates with already developedbiofilms. The plasma needle was placed vertically abovethe microtiter plate in line with the upper edge of eachwell (Figure 1).
Figure 1. Plasma needle with microtiter plate.
The distance between the tip of the plasma needle andthe surface of the sample in each well was fixed to 3 mm.The samples were treated by plasma operating at threedifferent powers (0.15, 0.9 and 1.6 W), and two flows ofhelium (0.5 and 1 slm) during three exposure times (30,60 and 120 s). The untreated wells were used as positivecontrols. All treatments were performed in triplicate andrepeated at least two times for each bacterial inoculumtested.
2.5. Quantification of biofilm
The content of a microplate was poured off and each wellwas washed three times with 300 µL of sterile phosphate-buffered saline (PBS; pH 7.2) to remove free floatingbacteria. After fixation of adherent biofilm with 150 µLof methanol per well for 20 min, the plates were emp-tied by flicking and left to air dry overnight in an in-verted position at room temperature. The biofilms were
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stained with 150 µL of 2% crystal violet for 15 min. Ex-cess stain was washed under running tap water. Afterthe plates were air dried, the dye bound to the adher-ent cells was resolubilized with 150 µL of 95% ethanol.The optical density (OD) of each well was measured at570 nm using Multiskan EX reader (Labsystems). Theresults obtained were averaged and expressed as num-bers. The cut-off OD (ODc) was defined as three stan-dard deviations (SD) above the mean OD of the neg-ative control [40]. The results were classified as fol-lows: OD≤ODc no biofilm production; ODc≤OD≤2xODcweak biofilm production; 2xODc≤OD≤4xODc moderatebiofilm production; 4xODc≤OD strong biofilm produc-tion. Statistical analysis (One-way ANOVA, Dunett test)was performed using SPSS statistical software package(SPSS 15.0 (Chicago, Illinois)). Statistical significancewas declared as p < 0.05.
3. Results
The study evaluated efficacy of the low-temperatureplasma at atmospheric pressure generated by an in-housedesigned plasma needle device against biofilm formationby a MRSA strain. Summarized results of the microtiterbiofilm assays are expressed as qualitative categories inTable 1.
Table 1. Qualitative evaluation of efficacy of low-temperature plasma
against biofilm formation by MRSA . Notations: No biofilm
formation (0); Weak biofilm formation (+); Moderate biofilm
formation (++); Strong biofilm formation (+++); Flow 1 (flow
rate of He of 0.5 slm); Flow 2 (flow rate of He of 1 slm).
Power [W] Exposure 104 CFU 105 CFU 106 CFUtime [s] flow 1 flow 2 flow 1 flow 2 flow 1 flow 230 ++ + ++ ++ ++ ++0.15 60 + + ++ + ++ +120 ++ + + + + +30 + + + + ++ ++0.9 60 + + + + + +120 0 0 0 0 + +30 0 0 + + + +1.6 60 0 0 0 0 + +120 0 0 0 0 + 0
The experimental design included four major variables:three different bacterial inocula were exposed to three dif-ferent powers of plasma and two flows of helium duringthree exposure times.It is obvious that the powers of 0.9 W and 1.6 W achieved acomplete inhibition of biofilm growth for testing inocula of
104 and 105 CFU. The highest power, 1.6 W, exhibited thiseffect irrespective of the treatment time, while the powerof 0.9 W completely prevented biofilm formation only afterthe longest exposure of 120 s. On the other hand, totalinhibition of biofilm production by 106 CFU required max-imal plasma parameters, namely power of 1.6 W, flow rateof 1 slm and exposure for 120 s.In order to quantitatively assess the antibiofilm activity ofthe non-thermal atmospheric plasma, the mean OD valuesof treated samples were compared to those of untreatedcontrols. The mean OD values with standard deviationsobtained at the flow rates of 0.5 slm and 1 slm are shownin Figures 2 and 3, respectively. All OD values equal to orlower than ODc values shown in Figures 2 and 3 indicateabsence of biofilm since ODc was defined as three SDsabove the mean OD of the negative control, i.e. wellscontaining growth medium only.Combination of lower flow rate and minimal plasma powerof 0.15 W was ineffective for all inocula and exposure times(Fig. 2). Higher plasma powers (0.9 W, 1.6 W) significantlydecreased biofilm production by 104 MRSA cells regard-less of the exposure time (Fig. 2A), while a decrease inbiofilm production by 105 MRSA cells required a longerexposure, i.e. 60 and 120 s (Fig. 2B). The biofilm produc-tion by the highest bacterial inoculum was not affected bythe plasma treatments at the flow rate of 0.5 slm (Fig. 2C).At the flow rate of 1 slm, plasma significantly reducedbiofilm formation in samples with 104 CFU, even when thesmallest power of plasma was applied, during all treat-ment times (Fig. 3A). As far as larger inocula are con-cerned, 105 and 106 CFU, higher plasma powers of 0.9and 1.6 W and exposure time of at least 60 s were neededfor significant reduction in biofilm growth (Fig. 3B and3C). The effects of non-thermal plasma on formed MRSAbiofilm were evaluated by using the same set of plasmatreatments. No significant reduction in biofilm was noted,even with maximal plasma parameters applied (data notshown).
4. Discussion
The use of atmospheric pressure non-thermal plasma hasbeen evaluated for many potential biomedical applica-tions, including eradication of microorganisms [8, 11]. Thecold plasma has been proven to be effective in terms ofmicrobial inactivation and surface decontamination andsterilization [41, 42]. Numerous studies showed activityof non-thermal plasma against different Gram-negativeand Gram-positive bacteria [13, 15, 43–46]. However,data on activity of cold atmospheric pressure plasma foreradication of biofilm produced by MRSA are still lim-
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Figure 2. Efect of non-thermal atmospheric plasma on MRSA biofilm for helium flow of 0.5 slm. Samples with different inoculum size of MRSA
((A) 104 CFU; (B) 105 CFU; (C) 106 CFU) were treated for three plasma powers (0.15 W, 0.9 W, 1.6 W) and three exposure times (30 s,
60 s, 120 s). Control samples were untreated cells. The results are presented as mean OD values of triplicates ±SD of two separate
experiments. ODc was defined as 3 SDs above the mean OD of the negative control. ∗p < 0.05 compared to untreated, control cells
(Dunett test).
ited [13, 47]. MRSA strains are among the leading causesof healthcare-associated infections and are a major con-cern for infection control programs. It is also generallyappreciated that the staphylococci, including MRSA, havethe ability to adhere to many types of surfaces and de-velop biofilms. MRSA biofilms, in addition to the mul-tiresistance of the bacterium, have innate resistance toantimicrobial agents, and, thus, new treatment strate-gies that target MRSA biofilm are needed. We carriedout a comprehensive in vitro investigation of the activ-ity of atmospheric pressure non-thermal plasma generatedby an in-house designed plasma needle against biofilmproduced by a clinically relevant MRSA strain. Assess-ment of a particular plasma source is important since theworking parameters for the application of different low-temperature sources of the atmospheric plasma are dif-ficult to be standardized, and are defined separately forevery single source.
The MRSA cell densities varied from 104 to 106 per welland the effects of changing the plasma parameters suchas power and flow rate at three different exposure timeswere evaluated. The results obtained clearly show thatthe low temperature atmospheric pressure plasma gen-erated by a plasma needle exhibited inhibitory effectsagainst MRSA biofilm growth. In general, inhibitory ef-fects of the plasma tested were positively correlated tothe plasma parameters. We found that effectiveness ofthe plasma was time and power dependent and that en-hanced anti-biofilm activity was also accomplished by ahigher helium gas flow. Namely, with a higher flow ratemore reactive plasma agents come in contact with bac-terial cells. The higher power delivered to the plasmameans that concentration of the radicals and ions is in-creased compared to the lower powers while still stayingwell within the limits of negligible temperature change.As a plasma needle produces negligible amount of ozone,in this case the most important radical is NO which is
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Figure 3. Efect of non-thermal plasma on MRSA biofilm for helium flow of 1 slm. Samples with different inoculum of MRSA ((A) 104 CFU; (B) 105
CFU; (C) 106 CFU) were treated for three plasma powers (0.15 W, 0.9 W, 1.6 W) and three exposure times (30 s, 60 s, 120 s). Control
samples were untreated cells. The results are presented as mean OD values of triplicates ±SD of two separate experiments. ODc was
defined as 3 SDs above the mean OD of the negative control. ∗p < 0.05 compared to untreated, control cells (Dunett test).
a potent antimicrobial agent, effective against a range ofGram-negative and Gram-positive bacteria, including S.aureus [48]. In our previous work we have shown thatplasma needle generates NO radicals and that amountof generated NO is highly dependent on the power de-livered to the plasma [37]. It was shown that with anincrease in power delivered to the plasma concentrationof NO increases. As another point we have to mentionthe abundance of ions created by a plasma needle whoseconcentration also increases with power. An increase inpower means a larger plasma volume and, thus, larger areais in direct contact with the plasma. The exact compositionof bactericidal agents produced by plasma varies depend-ing on geometry, composition of working gas, humidity,power, etc. The antimicrobial properties of NO may beelicited by direct modification of biomacromolecules or byformation of reactive nitrogen oxide species (RNOS) suchas peroxynitrite (OONO−), S-nitrosothiols (RSNO), nitro-gen dioxide (NO2), dinitrogen trioxide (N2O3), and dini-trogen tetroxide (N2O4). These reactive intermediates ex-
ert antimicrobial effects by inducing lipid peroxidation oraltering DNA according to Schairer et al. [49] RNOS cancause nitrosation of protein thiols and the nitrosylation ofmetal centres (Fe-S), ultimately modifying the functions ofproteins that are essential to cellular processes [50, 51].
The results of the present study show that biofilm inhibi-tion by the plasma, in addition to the plasma parameters,was also closely dependent on the inoculum size. For thelargest inoculum of bacteria, plasma treatment did not af-fect biofilm formation at the flow rate of 0.5 slm, even withthe maximum power and the longest exposure. Inhibitoryeffects of the plasma against biofilm produced by 106 bac-teria were observed only at the flow rate of 1 slm, in com-bination with other plasma parameters. Consistently highlevel of biofilm inhibition obtained for the smallest inocu-lum of 104 MRSA cells was not sensitive to the changes intreatment times. At the flow rate of 0.5 slm, plasma powerof 0.9 W was sufficient to decrease significantly biofilmformation by this inoculum, irrespective of the exposure
165
Inhibition of methicillin resistant Staphylococcus aureus by a plasma needle
time. At the higher flow rate, all combinations of plasmaparameters were effective in biofilm growth inhibition.
While the inhibitory effects of the cold plasma on biofilmformation by the MRSA strain tested in the present studywere apparent, the plasma treatments of formed biofilms,i.e. biofilms grown after 24 hours of incubation were in-effective. This may be related to the thickness of thebiofilm and the inability of bactericidal agents producedby plasma to penetrate a thick biofilm. Since eradicationof biofilm is essential for possible practical application ofthe nonthermal atmospheric plasma, further evaluation ofits effects on biofilm formed after 24 h as well as longerincubation periods is needed. In addition to the biofilmincubation period, all parameters of the plasma treatmentshould be optimized in the context of biofilm eradication.It opens a possibility of further tests depending on thetargeted substrates which would include extended periodand repeated treatments, higher powers, a different moreenergetic plasma (perhaps for non living substrates) andcombined treatment with other techniques. It is notewor-thy that we have shown that even with a higher powerthe thermal heating of the target is negligible and, thus,going to a higher power would lead to some effects.
5. Conclusion
In this study the in-house plasma needle device has beenproven to generate cold atmospheric pressure plasma thatis highly efficient for an in vitro prevention of MRSAbiofilm development. Under the specific conditions, com-plete inhibition of biofilm formation was noted even forthe inoculum as high as 106 MRSA cells. Therefore, theplasma application suggested by this study lies within thearea of inanimate surface decontamination/sterilization.As far as in vivo application is concerned, it should benoted that the same plasma treatments utilized againstMRSA biofilm had been previously tested for cytotoxicityon peripheral blood-derived mesenchymal stem cells andno cytotoxic effects were established [15].
We are well aware that the study provided results basedupon an in vitro experimental model, and that further re-search is needed for practical application within the areaof in vivo desinfection. In addition, further research intoeradication of formed biofilms by plasmas that producemore effects on surfaces is planned, such as a micro atmo-spheric pressure plasma jet and an atmospheric pressureplasma jet.
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